Health · Pharma & Biotech · 2 days ago
Rasonque data suggest room for other pancreatic cancer treatments
RevMed is studying Rasonque for pancreatic cancer.
New data suggest that patients with the most common KRAS mutation in the disease appeared to respond less often to the drug than the overall group of patients.
The data do not include response rates in the available information.
KRAS mutations are changes in a gene, and this one is the most common in pancreatic cancer.
The difference may leave room for other treatments for patients with this mutation.
The available information does not say what other treatments are being considered or what happens next.
New data on Revolution Medicines’ Rasonque showed a lower response rate among patients with the most common KRAS mutation in pancreatic cancer than in the overall patient population.
The article said the lower rate appeared to leave potential room for other treatments.
The data were reported by Endpoints News on October 9, 2026.
The article excerpt did not provide response-rate figures or further details.
- Who
- Patients with the most common KRAS mutation in pancreatic cancer, and the overall patient population treated with Rasonque.
- What
- Patients with the most common mutation appeared to have a lower response rate.
- When
- Endpoints News reported the data on October 9, 2026.
- Where
- Not stated.
- Why
- The lower response rate may leave an opening for other treatments.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Drug
- Rasonque
- Company
- Revolution Medicines
- Cancer type
- Pancreatic cancer
- Mutation
- The most common KRAS mutation
- Report date
- October 9, 2026
Sources
Related news
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
Brazil suspends Peptistrong supplement and orders all batches recalled
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
Daily painkiller use can hide the cause of ongoing pain
Swiss oncologist warns US drug pricing pressure could delay cancer therapies
